Company: ANIX
Filing Date: 2025-09-10
Form Type: S-3
Source: 0001493152-25-013010
Chunk: 2

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: S-3
Chunk 2
---
-267369), which was originally filed with the SEC on September 9, 2022 and declared effective on September 19, 2022, or the Prior Registration Statement. The aggregate filing fee paid in connection with such Unsold Securities was $8,764.10. Pursuant to Rule 415(a)(6) under the Securities Act, (i) the registration fee applicable to the Unsold Securities is being carried forward to this registration statement and will continue to be applied to the Unsold Securities, and (ii) the offering of the Unsold Securities registered on the Prior Registration Statement will be deemed terminated as of the date of effectiveness of this registration statement. If the registrant sells any of the Unsold Securities pursuant to the Prior Registration Statement after the date of the initial filing, and prior to the date of effectiveness, of this registration statement, the registrant will file a pre-effective amendment to this registration statement, which will reduce the number of Unsold Securities included on this registration statement.

<div align='center'>EXPLANATORY NOTE</div>

We are filing this registration
statement with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process to replace
our prior registration statement (File No. 333-267369) (the “Prior Registration Statement”) that will expire on
September 19, 2025, in accordance with applicable SEC regulations. Pursuant to Rule 415(a)(6) under the Securities Act,
the offering of securities under the Prior Registration Statement will be deemed terminated as of the date of effectiveness of this registration
statement.

This registration statement contains two prospectuses, a base prospectus for the purpose of implementing a “shelf” registration process and a sales agreement prospectus for the purpose of implementing a $100,000,000 “at-the-market” offering program under the shelf registration statement.

The base prospectus covers the offering, issuance and sale by us of up to $200,000,000 of our common stock (including the $100,000,000 “at-the-market” offering program), preferred stock, purchase contracts, warrants, subscriptions rights, depositary shares, debt securities and/or units. The sales agreement prospectus covers our offering, issuance and sale of up to $100,000,000 of our common stock under a sales agreement with Cantor Fitzgerald & Co.

The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in one or more prospectus